Nabla Bio, an OpenAI-backed Massachusetts biotech company, said its JAM-2 model generated high-affinity antibody candidates against 26 targets and that it expects first-in-human trials of AI-designed …
Chai Discovery is pioneering a shift in biopharma by using generative AI for deterministic, sub-angstrom structural engineering, replacing traditional mouse immunization in drug design. The company's …
Chai Discovery, a San Francisco-based AI drug discovery company whose platform is used by Eli Lilly, Pfizer, and Novartis, is hiring a Scientist for Protein Design to work on-site with its science tea…
Chai Discovery, a San Francisco-based company building AI models for biochemical structure and interaction, posted an internship listing despite stating it does not offer internships, inviting interes…
Reed Jobs, son of Apple cofounder Steve Jobs, said on the Sabrina Halper Show that Silicon Valley's 'energy' has moved to San Francisco, citing OpenAI, Anthropic, and Chai Discovery, and attributing t…
Chai Discovery, a San Francisco-based biotech startup, released Chai-3, a generative AI model for molecular design that doubles the success rate of its predecessor in creating therapeutic antibodies, …
Chai Discovery, an OpenAI-backed AI drug development startup valued at $4 billion, is at the center of a shift in the pharmaceutical industry as major AI tools deals were announced at the JPMorgan hea…
Relation Therapeutics unveiled MORGAN, a cellular foundation model, and an expanded collaboration with GSK worth up to $110 million to generate the biological data needed to train it. The London start…
Chai Discovery Inc. has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion, as the AI drug discovery company signs licensing agreements with Pfizer Inc., Eli Lilly …
OpenAI researcher Miles Wang is leaving to launch an AI drug discovery startup in talks to raise about $200 million at a $2 billion valuation, with Lightspeed in discussions to lead the round, though …
Chai Discovery raised $400 million in a Series C round led by Index Ventures, tripling its valuation to $3.8 billion in seven months as the AI drug discovery startup's generative models are deployed a…
Chai Discovery raised $400 million in a Series C round, tripling its valuation to $3.8 billion in seven months, after securing a deal with Novartis. The OpenAI-backed AI drug discovery company's rapid…
OpenAI researcher Miles Wang is in advanced talks to launch an AI drug discovery startup at a $2 billion valuation, with Lightspeed Venture Partners reportedly leading a $200 million round, according …
OpenAI researcher Miles Wang is leaving the ChatGPT maker to launch an AI drug discovery startup valued at $2 billion, with plans to raise about $200 million from Lightspeed, according to sources. The…
Chai Discovery has raised $400 million in a Series C round at a $3.8 billion valuation, tripling its valuation in seven months. The OpenAI-backed drug discovery startup, founded in 2024, builds AI mod…
OpenAI-backed Chai Discovery closed a $400 million funding round at a $3.8 billion valuation on July 14, tripling its price tag in seven months. The Index Ventures-led round positions the company as A…
SandboxAQ has partnered with Anthropic to integrate its physics-based AI models, known as Large Quantitative Models (LQMs), into Claude, allowing researchers to perform complex drug discovery and mate…